FDA Emergency Use Authorization is granted for Paxlovid for the treatment of mild to moderate COVID-19 .
The treatment includes nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which was specifically designed to block the activity of the SARS-CoV-2 Mpro, an enzyme that the coronavirus needs to replicate.
Related news and insights
Brilacidin ,a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus
Novavax, Inc. announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.
Novavax, Inc. announced the Australian Therapeutic Goods Agency (TGA) has granted expanded approval for provisional registration of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adolescents aged 12 through 17.